臨床泌尿器科76巻11号

2022年10月発行

特集 限局性前立腺癌診療バイブル―このへんでキッチリと前立腺癌診療の“あたりまえ”を整理しよう！ 〈放射線治療〉

局所進行性前立腺癌に対する外部放射線治療の実際（粒子線治療も含む）

著者： 相澤理人¹

所属機関： ¹京都大学医学部附属病院放射線治療科

ページ範囲：P.830 - P.836

▶ポイント

・外部放射線治療は，局所進行前立腺癌に対する主要な治療手段の1つと位置づけられている．

・近年，寡分割照射の臨床導入，併用ホルモン治療やリンパ節転移を伴う症例への治療に関する新たなエビデンス報告，粒子線治療の保険収載など，本分野における変化は著しい．

・根治的外部放射線治療は，今後もさらに中心的な役割を担っていくものと考えられる．

参考文献

1） 日本泌尿器科学会 （編） : 前立腺癌診療ガイドライン2016年度版. メディカルビュー社, 大阪, 2016

2） Mohler JL, et al : NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 4. 2022　https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf （2022年8月1日閲覧）

3） Mottet N, et al : EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. 2022　https://d56bochluxqnz.cloudfront.net/documents/pocket-guidelines/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Pocket-on-Prostate-Cancer-2022.pdf （2022年8月1日閲覧）

4） Zaorsky NG, et al : What Is the Ideal Radiotherapy Dose to Treat Prostate Cancer? A Meta-Analysis of Biologically Equivalent Dose Escalation. Radiother Oncol 115 : 295-300, 2015

5） Vogelius IR, et al : Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy : A Meta-Analysis of Randomized Trials. Int J Radiat Oncol Biol Phys 100 : 858-865, 2018

6） Bolla M, et al : Duration of Androgen Suppression in the Treatment of Prostate Cancer. N Engl J Med 360 : 2516-2527, 2009

7） Denham JW, et al : Short-Term Androgen Suppression and Radiotherapy versus Intermediate-Term Androgen Suppression and Radiotherapy, with or without Zoledronic Acid, in Men with Locally Advanced Prostate Cancer （TROG 03.04 RADAR） : 10-Year Results from a Randomised, Phase 3, Factorial Trial. Lancet Oncol 20 : 267-281, 2019

8） Horwitz EM, et al : Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02 : A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer. J Clin Oncol 26 : 2497-2504, 2008

9） Nabid A, et al : Duration of Androgen Deprivation Therapy in High-Risk Prostate Cancer : A Randomized Phase III Trial. Eur Urol 74 : 432-441, 2018

10） Zapatero A, et al : High-Dose Radiotherapy with Short-Term or Long-Term Androgen Deprivation in Localised Prostate Cancer （DART01/05 GICOR） : A Randomised, Controlled, Phase 3 Trial. Lancet Oncol 16 : 320-327, 2015

11） Cooperberg MR, et al : Trans-Pacific Variation in Outcomes for Men Treated with Primary Androgen-Deprivation Therapy （ADT） for Prostate Cancer. BJU Int 117 : 102-109, 2016

12） Ito K, et al : Oncological Outcomes for Patients with Locally Advanced Prostate Cancer Treated with Neoadjuvant Endocrine and External-Beam Radiation Therapy Followed by Adjuvant Continuous/Intermittent Endocrine Therapy in an Open-Label, Randomized, Phase 3 Trial. Cancer 126 : 3961-3971, 2020

13） Spratt DE, et al : Prostate Radiotherapy with Adjuvant Androgen Deprivation Therapy （ADT） Improves Metastasis-Free Survival Compared to Neoadjuvant ADT : An Individual Patient Meta-Analysis. J Clin Oncol 39 : 136-144, 2021

14） Asbell SO, et al : Impact of Surgical Staging in Evaluating the Radiotherapeutic Outcome in RTOG #77-06, a Phase III Study for T1BN0M0 （A2） and T2N0M0 （B） Prostate Carcinoma. Int J Radiat Oncol Biol Phys 40 : 769-782, 1998

15） Pommier P, et al : Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study. Int J Radiat Oncol Biol Phys 96 : 759-769, 2016

16） Roach M, et al : Sequence of Hormonal Therapy and Radiotherapy Field Size in Unfavourable, Localised Prostate Cancer （NRG/RTOG 9413） : Long-Term Results of a Randomised, Phase 3 Trial. Lancet Oncol 19 : 1504-1515, 2018

17） Murthy V, et al : Prostate-Only versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer （POP-RT） Outcomes from Phase III Randomized Controlled Trial. J Clin Oncol 39 : 1234-1242, 2021

18） Morgan SC, et al : Hypofractionated Radiation Therapy for Localized Prostate Cancer : An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol 36 : JCO1801097, 2018

19） Royce TJ, et al : Conventional versus Hypofractionated Radiation Therapy for Localized Prostate Cancer : A Meta-Analysis of Randomized Noninferiority Trials. Eur Urol Focus 5 : 577-584, 2019

20） Widmark A, et al : Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer : 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial. Lancet 394 : 385-395, 2019

21） Nihei K, et al : A Japanese Multi-Institutional Phase II Study of Moderate Hypofractionated Intensity-Modulated Radiotherapy with Image-Guided Technique for Prostate Cancer. Int J Radiat Oncol Biol Phys 111 : e288, 2021

22） Ventimiglia E, et al : A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-Positive Prostate Cancer. Eur Urol Oncol 2 : 294-301, 2019

23） James ND, et al : Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer : Data from Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol 2 : 348-357, 2016

24） Sheets NC, et al : Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer. JAMA 307 : 1611-1620, 2012

25） Iwata H, et al : Long-Term Outcomes of Proton Therapy for Prostate Cancer in Japan : A Multi-Institutional Survey of the Japanese Radiation Oncology Study Group. Cancer Med 7 : 677-689, 2018

26） Nomiya T, et al : A Multi-Institutional Analysis of Prospective Studies of Carbon Ion Radiotherapy for Prostate Cancer : A Report from the Japan Carbon Ion Radiation Oncology Study Group （J-CROS）. Radiother Oncol 121 : 288-293, 2016